

1 Molecular dynamics simulations reveal molecular mechanisms for the gain and

2 loss of function effects of four *SCN2A* variants

3 Nisha Bhattarai^{1, #}, Ludovica Montanucci^{1,*}, Tobias Brünger², Eduardo Pérez-Palma³, William
4 Martin¹, Iris Nira Smith¹, Charis Eng¹, Feixiong Cheng¹, Ingo Helbig^{4,5,6,7}, Rikke S Møller^{8,9},
5 Andreas Brunklaus^{10,11}, Stephanie Schorge¹², Dennis Lal^{1,2,13,14,*}

6

7 ¹Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA.

8 ²Cologne Center for Genomics (CCG), University of Cologne, Cologne, 50931, Germany

9 ³Universidad del Desarrollo, Centro de Genética y Genómica, Facultad de Medicina Clínica Alemana. Santiago, Chile.

10 ⁴Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

11 ⁵The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

12 ⁶Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA
13 19104, USA.

14 ⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.

15 ⁸Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.

16 ⁹Department for Regional Health Research, University of Southern Denmark, Odense, Denmark.

17 ¹⁰The Paediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK.

18 ¹¹Institute of Health and Wellbeing, University of Glasgow, UK.

19 ¹²Department of Neuroscience, Physiology, and Pharmacology, UCL, London WC1E 6BT, UK

20 ¹³Stanley Center of Psychiatric Research, Broad Institute of Harvard and MIT, 75 Ames Street, Cambridge, 02142,
21 MA, USA

22 ¹⁴Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH 44106, USA.

23 [#]Present address: Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine,
24 Cleveland, OH, 44106, USA

25 ^{*}Present Address: Center for Neurogenetics, Department of Neurosciences, University of Texas Houston, TX

26 Correspondence: Dennis.Lal@uth.tmc.edu

27

28

29 **ABSTRACT**

30 *SCN2A* gene disorders cover a wide range of medical conditions, from epileptic encephalopathies
31 to neurodevelopmental disorders. The variants of these disorders, studied through
32 electrophysiology, show complex behaviors that go beyond simple classification as either gain or
33 loss of function. In our study, we simulated the biophysical effects of variants (*R937C*, *V208E*,
34 *S1336Y*, and *R853Q*) to understand their impact. Our findings reveal that all these variants
35 negatively affect the structural stability of the gene, with *R937C* being the most unstable.
36 Specifically, *R937C* disrupts important charged interactions affecting sodium ion flow, while
37 *S1336Y* introduces a new interaction that impacts the channel's inactivation gate. Conversely, the
38 variants *V208E* and *R853Q*, which are located in the voltage-sensing domains, have opposite
39 effects: *R853Q* increases compactness and interaction, whereas *V208E* shows a decrease. Our
40 computer-based method offers a scalable way to gain crucial insights into how genetic variants
41 influence channel dysfunction and contribute to neurodevelopmental disorders.

42

43 **AUTHOR SUMMARY**

44 Despite numerous advancements in computational methods for predicting variant pathogenicity in
45 the *SCN2A* gene, understanding the precise biophysical molecular mechanisms associated with
46 each variant at the atomic level remains a challenge. Presently, variants are predominantly
47 categorized as either gain or loss of function, often overlooking critical structural details associated
48 with these variants. This study focuses on elucidating the molecular mechanisms linked to the four
49 most common *SCN2A* variants using all-atom molecular dynamics simulations, employing three
50 replicas for each system. Our findings offer insights into the potential mechanisms underlying
51 these four variants, thereby providing explanations for the observed electrophysiological

52 outcomes. This investigation significantly contributes to enhancing our comprehension of how
53 *SCN2A* variants manifest in various diseases. It underscores the importance of unraveling the
54 biophysical properties underlying potential disease mechanisms, which could potentially enhance
55 diagnostic and therapeutic strategies for patients afflicted with *SCN2A*-related disorders.

56

57 INTRODUCTION

58 The sodium channel Nav1.2 protein, encoded by the *SCN2A* gene, belongs to the family of voltage-
59 gated sodium ion channels (VGSCs) which are a family of integral membrane proteins that play a
60 critical role in initiating and propagating action potentials in excitable cells(1–4). In response to
61 membrane depolarization, VGSCs change their conformation opening the pore, allowing the
62 passage of Na^+ ions in the cell(1). On structure, VGSCs are heteromultimeric transmembrane
63 proteins and consist of a 260 kDa alpha subunit which can be coupled with one or two 33-36 kDa
64 beta subunits. These alpha subunits are large, single-chain polypeptides consisting of about 2000
65 amino acids and arranged in four homologous domains, namely D1 to D4. Each domain consists
66 of six transmembrane helical segments S1 through S6. Segments S1-S4, also known as voltage-
67 sensing domain (VSD), regulate pore opening upon membrane depolarization. The VSD domains
68 are connected to the pore domain by a linker region between S4 and S5 segments. Segments S5-
69 S6 of each domain come together to form a Na^+ ion-selective pore region. This region also includes
70 a selectivity filter (SF), the narrowest part of the pore which is formed by P-loops (the region
71 between S5-S6 of each domain), and the inactivation gate, which is an intracellular loop
72 connecting D-III and D-IV, which acts as a “plug” in the closing and opening of the channel.
73 depolarization section of the pore facing the cytoplasm is formed by the combination of S5 and S6
74 segments from all four domains. The voltage sensors, pore region, and inactivation gate are crucial

75 parts of the sodium channel as the majority of the pathogenic mutations in SCN genes are located
76 in those regions(2,5,6).

77 Given their crucial role in brain functions, genetic variants in VGSCs genes are known to cause a
78 wide spectrum of neurodevelopmental disorders, which can occur with or without epilepsy and
79 have different levels of severity, onset age, and response to medication(7–9). In particular, the
80 *SCN2A* gene is known to cause a wide range of neurodevelopmental disorders. In Clinvar, the most
81 comprehensive database of the relationship between variants and disease phenotypes, 1839 patient
82 variants in the *SCN2A* gene are reported, of which 449 are classified as pathogenic or likely
83 pathogenic (accessed 12/2022). Variants in *SCN2A* have been associated with multiple disorders
84 including autism spectrum disorder (ASD), developmental and epileptic encephalopathies (DEE),
85 intellectual disability (ID), benign familial neonatal/infantile seizures (BFNIE), and
86 schizophrenia(9–12). Among all VGSCs, *SCN2A* also emerges as the gene with the strongest
87 autism spectrum disorder association(7,13,14).

88 At an electrophysiological level, *SCN2A* variants can modify the protein structure and its
89 consequent ability to carry out its channel function by altering specific functional properties, such
90 as causing a voltage shift of activation or inactivation, modifying the peak current, cell surface
91 expression etc.(15–17). The overall net effect of these modifications caused by the variant is often
92 summarized into one of the two functional categories of gain (GoF) and loss (LoF) of the ion
93 channel function, depending on whether the variant enhances or reduces the overall action of the
94 protein. These molecular effects of missense variants can determine the observed phenotype and
95 even affect susceptibilities to pharmacological treatments. For example, in *SCN2A*-related
96 epileptic encephalopathies, GoF missense variants are associated with an earlier seizure onset and
97 response to sodium channel blockers. In contrast, LoF missense variants in *SCN2A* are associated

98 with autism(18,19) and do not benefit from antiepileptic drugs(7,20). Although these molecular
99 effects (GoF vs LoF) studied using electrophysiological experiments are crucial in identifying
100 clinical and/or molecular phenotypes and treatments, they do not cover the entire spectrum of
101 molecular disease mechanisms caused by a variant in the Nav1.2 channel(8,19) and are an over-
102 simplification of the complex protein functionalities. For instance, if a patient has a GoF variant
103 causing epilepsy, the sodium current might increase due to different molecular mechanisms such
104 as a delayed closing of the inactivation gate, or a wider opening of the pore region(7,21). A recent
105 study that investigated the functional properties of more than 30 *SCN2A* variants showed that there
106 is a range of altered channel properties that do not fit into a simple binary GoF vs LoF
107 classification(22). The biophysical effects behind the molecular electrophysiological
108 heterogeneity across different missense variants is not understood.

109 Molecular dynamics (MD) simulations have been extensively used to capture the dynamics of
110 molecular systems over time, offering a level of detail that is difficult to achieve through
111 experimental techniques alone. MD simulations have proven valuable for studying various
112 biomolecular processes, including conformational changes, protein folding, ligand-binding site
113 prediction, and the effects of mutations at an atomic level(23,24). However, the application of MD
114 simulations to sodium ion channels has been relatively limited, mainly due to challenges arising
115 from their large protein structures, and limited availability of the human protein structure for all
116 conformations. Initially, computational studies on sodium ion channels focused on only the pore
117 region to study Na^+ permeation, following the crystallization of the bacterial sodium channel
118 structure(3,25)(26–28). Subsequently, with the publication of the first eukaryotic sodium channel
119 structure, similar studies were carried out to study Na^+ permeation pathways in eukaryotes (29,30).
120 Focusing solely on the pore section, however, limits our ability to observe variant effects on the

121 overall conformation of the entire protein and on other essential regions, such as the voltage-
122 sensing domain and the inactivation gate. These regions play critical roles in the channel's function,
123 and understanding their structure and dynamics is crucial for a comprehensive investigation.
124 Besides the observation of Na^+ ion permeation, MD simulations have also been employed to
125 understand the mechanisms of drug binding to sodium ion channels (29,31,32)-(33). There has
126 been a very limited exploration of the effects of variants in VGSCs using MD simulations.
127 Recently, Bielopolski et al. (2022) performed virtual patch analysis via molecular dynamics
128 simulations on six patient variants in sodium channels associated with different disease phenotypes
129 (Dravet, epilepsy, and autism). By studying the release time of sodium ions at the DEKA motif,
130 they predicted the functional effect of a variant that was well in agreement with existing patch
131 clamp analysis for four out of the six variants. However, this study was limited to a relatively short
132 simulation time of 120 ns and also did not provide information on the underlying molecular
133 mechanism of these pathogenic variants. One of the primary reasons for the limited scope of these
134 studies, including the use of short simulation times and the focus on the pore region, is the large
135 size of the $\text{Na}_v1.2$ protein structure, which makes MD simulations very computationally time-
136 consuming.

137 In this study, we performed molecular dynamics simulations of four common $\text{Na}_v1.2$ variants to
138 unravel molecular disease mechanisms associated with these variants and their relationship with
139 *in-vitro* molecular read-outs. We selected four variants (*R937C*, *V208E*, *S1336Y*, and *R853Q*) in
140 the *SCN2A* gene based on their high prevalence in *SCN2A* patients (34,35)(Total: 22 individuals,
141 Table 1) and on their distinct molecular read-outs, classified as either gain or loss of function based
142 upon *in-vitro* molecular readouts. Each of the selected variants (*R937C*, *V208E*, *S1336Y*, and
143 *R853Q*) within the *SCN2A* gene has been electrophysiologically tested and exhibits distinctive

144 molecular characteristics and clinical phenotypes, including autism spectrum disorder (ASD) for
145 *R937C*, the mild benign Familial Neonatal-Infantile Epilepsy (BFNIE) for *V208E*, the severe
146 Early-Onset Epileptic Encephalopathy (EOEE) for *S1336Y*, and severe Developmental and
147 Epileptic Encephalopathy (DEE) for *R853Q*(36–38). In this work, we carried out MD simulations
148 for wild-type Nav1.2 protein as well as the four selected variants to uncover the disease associated
149 mechanisms and compared this mechanism using experimental read-outs for these four variants
150 by analyzing different biophysical properties exhibited at the atomic level. We further identified
151 different mechanisms resulting in a loss/gain of function, providing greater detail and
152 understanding of the variant effect.


153 **RESULTS**

154 **Assessment of *SCN2A* mutations on the overall structural stability and compactness of**
155 **Nav1.2 systems**

156 To assess the stabilities of the Nav1.2 systems and examine their structural variation and dynamic
157 alterations, we measured the root mean square deviation (RMSD) for the wild-type and each
158 variant structure. The RMSD calculation was performed for the backbone of the protein and for a
159 period of 500 ns (nanoseconds). We found that the average RMSD values across systems were
160 stable after 500 ns at about ~0.37 nm of deviation from the initial conformation. In particular, the
161 deviations from the initial conformations for the WT and the *R937C*, *V208E*, *S1336Y*, and *R853Q*
162 variant structures are 0.37, 0.41, 0.36, 0.32, and 0.39 nm, respectively (Figure 1a). These
163 deviations indicate that the simulated protein-membrane complexes remained well stabilized
164 throughout the simulation. We observed a greater RMSD change for the *R937C* variant structure
165 at around 250 ns, when RMSD increased from ~0.41nm to ~0.55nm. The *R937C* variant structure
166 exhibited the greatest deviation from its initial conformation compared to the other variant

167 structures. Furthermore, the *R937C* structure had the highest spread of RMSD values over time.
168 These findings indicate that all systems reached stability within the simulated time frame, and the
169 *R937C* variant structure displays the greatest degree of conformational flexibility.
170 We also investigated the compactness of the protein structures, which often correlates with protein
171 compactness. To achieve this, we plotted the time-dependent radius of gyration (R_g) of the
172 protein's main chain, which is a measure of compactness, for the WT and the variant structures,
173 using our simulation trajectory (Figure 1b). Our results revealed that all mutants underwent a
174 structural change and were on average significantly less compact compared to the WT variant
175 ($WT_{Rg} = 3.35$ nm, $R937C_{Rg} = 3.41$ nm, $V208E_{Rg} = 3.40$ nm, $S1336Y_{Rg} = 3.40$ nm, $R853Q_{Rg} = 3.39$
176 nm, Wilcoxon rank sum test $P < 2.2e^{-16}$). Across all mutants, the structure of *R937C* exhibited the
177 widest range of compactness change across the simulation time (Figure 1c).
178 Notably, the increase in R_g after 250 ns was well-correlated with the increase in RMSD observed
179 after 250 ns (Figure 1a), indicating structural modifications in the protein.

180




181

182 **Figure 1** All simulated structures reach stabilization over the course of 500ns. All variant structures are less
183 stable (a) and less compact (b and c) than the wild-type structure. The *R937C* structure is the least stable and
184 least compact. Root-mean-square deviation (RMSD) (a) and radius of gyration (R_g) (b) plotted against
185 simulation time for wild-type (WT) (black), *R937C* (red), *V208E* (blue), *S1336Y* (green), and *R853Q* (magenta)
186 structures. c) Box plot of the radius of gyration. The colors in the legend correspond to the following variant
187 structures: red for *R937C*, blue for *V208E*, green for *S1336Y*, and magenta for *R853Q*. Black represents the MD
188 simulation of the wild-type structure.
189

190 **Principal component analysis of the conformational space and free energy landscape**

191 We further analyzed the conformational sampling space of wild-type (WT) and variant protein
192 structures by examining the first two principal components (PC1 and PC2) obtained from the
193 principal component analysis (PCA) of the positional fluctuation covariance matrix of protein C α
194 carbon atoms. The projection of backbone atoms onto the essential subspace, defined by principal
195 components 1 and 2, was used to visualize the conformational sampling of the proteins. PC1 and
196 PC2 for each protein structure were plotted at different time intervals of 100 ns each (Figure 2a).
197 Each interval was colored according to a color gradient going from light green (time interval from
198 0 to 100 ns) to dark green (time interval from 400 to 500 ns) to show how the conformations
199 evolved over time. Figure 2a shows that all variant structures explored more conformational space
200 than WT, and all proteins reached their stable conformation after 300 ns, as evidenced by the clear
201 overlap of conformations between the 300-400 ns interval and the 400-500 ns interval, except for
202 the *S1336Y* structure which appeared to have multiple transient conformations.
203 To investigate the stability of the conformational states explored by the considered structures
204 during our simulations, we calculated the Gibbs free energy landscape using PCA, with the
205 positional fluctuations covariance matrix of C α atoms as reaction coordinates. The global energy
206 minima associated with the conformational state of WT, *R937C*, *V208E*, and *R853Q*, represented
207 by the red color of the color gradient code of Figure 2b, were achieved after 300 ns for each
208 structure. However, for *S1336Y*, we observed multiple low free energy conformations, colored red
209 in Figure 2b. These results suggest that although most variant structures and WT reached their
210 stable conformation at almost the same time with minimum energy, the conformational space of
211 mutants was more spread out before reaching their stable conformation after 300 ns.



212

213 **Figure 2** a) All variant structures explored more conformational space than WT. Projection of the Ca atoms of
214 the WT and the four variant structures on the essential subspace, defined by the first two eigenvectors (PCs) of
215 the covariance matrix of the wild-type protein. The colors indicate the 100 ns-long consecutive time intervals in
216 the simulation, ranging from the lighter green color indicating a time interval from 0 to 100 ns, to the darkest
217 green color indicating a time interval from 400 to 500 ns. b) The free energy landscape analysis shows that after
218 300 ns all systems stabilize on the lowest free energy conformational state. Free energy landscape analysis for
219 WT and its variant structures. The free energy landscape was obtained using the projections of the protein's Ca
220 atoms position vectors onto the first two principal components as reaction coordinates. The free energy values,
221 calculated from the distribution density, are given in kJ/mol and colored according to the color gradient detailed
222 in the color bar. The red spots indicate the regions corresponding to the conformations with the lowest free
223 energy and therefore more stable.


224

225 **Pore radius**

226 The pore region plays a crucial role in determining the selectivity and conductance properties of
227 all ion channels. To analyze the changes introduced by the variants into the pore region, we
228 compared the pore radius along the membrane axis in WT and variant structures, once the systems
229 reached stability. Given that all analyzed structures reached stability after approximately 300 ns,
230 we focused, for pore radius calculations, on the last 100 ns of the simulation in the time interval
231 from 400 to 500 ns. We, therefore, obtained the average protein structure within the 400-500 ns
232 time interval and utilized this structure to calculate the pore radius.

233 The results of the changes induced to the pore radius by the variants are shown in Figure 3. Figure
234 3a presents a grid surface representation of the pore radius of the WT structure that was color-
235 coded according to radius values, where blue indicates pore regions with radius $>1.6 \text{ \AA}$, green
236 indicates pore regions with radius comprised within 1.1 \AA and 1.6 \AA , and red indicates pore regions
237 with radius $<1.1 \text{ \AA}$. Blue, therefore, indicates the most expanded regions of the pore, while red
238 represents the most contracted ones. Figure 3b displays the grid surface representation of the pore
239 radius for each variant structure with the same color code. Figure 3c shows the variation of the
240 radius profile along the membrane axis for all variants when compared with WT (black line). We
241 found that at the extracellular section of the pore, which includes the selectivity filter, the pore
242 profiles of the variant structures exhibited minimal changes in the pore radius compared to the WT
243 structure, with the lines in Figure 3c almost superimposed. However, more marked alterations were
244 observed in the intracellular section of the pore. For all variant structures, we observed a reduction
245 of the pore radius at the intracellular region in comparison to WT. The minimum value for the
246 radius in the intracellular region is 1.38 \AA for WT and 0.98 \AA , 1.1 \AA , 1.13 \AA and 0.36 \AA for *R937C*,
247 *V208E*, *S1336Y*, and *R853Q*, respectively. These results show that the two variant structures
248 *R853Q* and *R937C* exhibit greater pore radius contraction (Figure 3b). In these two variant
249 structures, the observed pore contraction makes the pore radius equal (for *R937C*) and smaller (for
250 *R853Q*) than the radius of the Na^+ ion, which has been estimated to be 0.98 \AA (51). This pore
251 contraction to the dimension of the Na^+ ion is likely creating a bottleneck in the pore which impedes
252 the flow of sodium ions, subsequently causing the loss of channel function. The molecular readouts
253 for these two variant structures indicate loss of function (LoF). Conversely, while the *V208E* and
254 *S1336Y* variant structures also undergo pore contraction, their minimum radius (1.1 \AA and 1.13 \AA
255 for *V208E* and *S1336Y*, respectively) is still greater than that of the Na^+ ion, therefore this pore

256 contraction is not enough to impede the passage of Na^+ ions. Interestingly, the molecular readouts
257 for these two variant structures indicate GoF and GoF/mixed effects.



258
259 **Figure 3** All variant structures exhibit a pore contraction in the intracellular section of the pore. The minimum
260 radius for the *R937C* and *R853Q* variant structures becomes equal and smaller than the radius of the sodium ion
261 (0.98 Å). In (a) and (b) is depicted the color-coded grid surface representation of the pore radius of the Nav1.2
262 ion channel protein, in the WT (a) and in the four (*R937C*, *V208E*, *S1336Y*, and *R853Q*) variant structures (b).
263 Blue, green, and red indicate pore segments and are color-coded as >1.6 Å (blue), 1.1 Å-1.6 Å (green), and <1.1
264 Å (red). In (a) the selectivity filter and the intracellular section of the pore are highlighted by dotted lines. c) Pore
265 radius plotted against the membrane axis. In all plots, the black line represents the WT pore radius, while the
266 radius of the variant structures is depicted using their respective colors (red for *R937C*, blue for *V208E*, green
267 for *S1336Y*, and magenta for *R853Q*).

268
269 **R937C disrupts two salt bridge interactions and alters the overall net charge at the selectivity
270 filter**


271 Upon examining the local modifications induced by the *R937C* variant, which is situated near the
272 selectivity filter, we observed notable changes in interactions due to the substitution of arginine
273 with cysteine. In the WT system, the positively charged R937 residue established two salt-bridge
274 interactions with two negatively charged residues, E942 and E945. These interactions are absent

275 in the *R937C* system (Figure 4b). To further assess the stability of these interactions, we plotted
276 the distance from the E942 and the E945 residues of both wild-type R937 residue and variant
277 *R937C* residue, throughout the simulation. Figure 4c illustrates the distance between *R937C*-E942
278 and *R937C*-E945 for both the WT (black) and variant (red) systems. The distance between both
279 salt bridges remained stable in the WT setup, averaging approximately 3 Å apart. However, in the
280 *R937C* setup, the distance between C937-E942 averaged around 8 Å, while the distance between
281 C937-E945 was approximately 12 Å.

282 To complement these findings, we also calculated the hydrogen bond occupancy between *R937C*
283 and residues within a 3.5 Å distance from R937 in both WT and *R937C*. In MD simulation,
284 hydrogen bond occupancy reflects the percentage of simulation time in which these interactions
285 are formed. As depicted in Figure 4d and 6e, we observed that the WT system showed strong
286 occupancy for the R937-E945 and R937-E942 interactions, 184% and 195% , respectively. This
287 indicates that in the WT system, these two interactions were present during the entire simulation
288 period of 500 ns. In contrast, in the *R937C* system, these occupancies decreased to 41% (C937-
289 E942) and 0% (C937-E945). We also noted a change in occupancy with L933, which exhibited
290 occupancies of 111% in the WT and 214% in the *R937C* variant. This alteration in interaction with
291 L933 suggests that, possibly, the substitution of cysteine favors interaction with L933 rather than
292 forming the two salt bridge interactions present in the wild-type form.

293 Recent electrophysiological experiments indicate that the *R937C* variant results in a complete loss
294 of conductance, with a measured whole-cell current of 0 mA(36). Based on our findings, we
295 propose that the absence of the two salt bridge interactions at the selectivity filter leads to a
296 modification of the net charge at the entrance of the pore, rendering it negative. Consequently, this
297 negative charge may hinder the movement of sodium ions through the pore, ultimately resulting

298 in the loss of conductance in the channel. These results align well with the experimental
299 observations.




300
301 **Figure 4** (a) Top view of the Na_v1.2 model highlighting the position of R937 in the WT structure. (b) Close-up
302 view showcasing the electrostatic interactions formed between R937 and E942 and E945 in WT. (c) in variant
303 R937C. (d) Simulation time-dependent distance profiles of R937C-E942 and R937C-E945, represented by black
304 (WT) and red lines (C937) respectively, illustrating the differences between the WT and R937C. (e) Heatmap of
305 hydrogen bond occupancy analysis reveals the formation of hydrogen bonds by R937 and C937 with residues
306 within a 3.5 Å cutoff distance.
307

308 **S1336Y forms a new interaction with the inactivation gate possibly hampering its ability to
309 switch between the open and closed conformations**

310 To investigate molecular mechanisms associated with GoF/mixed variant S1336Y, we examined
311 the interactions formed by amino acid at position 1336 in both WT (S1336) and variant (Y1336)
312 systems. The S1336 residue is located in domain 3 and it is part of the S4/S5 linker helix. When
313 the serine is mutated into tyrosine at position 1336, a new hydrogen bond interaction is introduced
314 between Y1336 and D1474, which is located in the D3-D4 connect section and is part of the
315 inactivation gate. This interaction was quantified by plotting the distance between residue D1474

316 and S1336 or Y1336 for both the wild-type (WT) and variant systems, as shown in Figure 5c. The
317 plot revealed that in the WT system, the distance between S1336 and D1474 was around 8 Å, while
318 the distance between Y1336 and D1474 was smaller than 4 Å.
319 To further investigate whether this interaction changes the exposure of the inactivation gate to the
320 solvent, the solvent-accessible surface area (SASA) for the inactivation gate was computed and
321 plotted for both the WT and the variant, as shown in Figure 5d. The SASA plot revealed that the
322 solvent exposure of the inactivation gate was lower in the variant (58 nm^2) compared to the WT
323 (62.5 nm^2), suggesting that this new interaction stabilizes the inactivation gate. Overall, these
324 findings suggest that a serine to tyrosine mutation at position Y1336 leads to the formation of a
325 hydrogen bond interaction with residue D1474 which can significantly impact the structure and
326 stability of the inactivation gate. This might also result in a modified ability of the inactivation
327 gate to switch between open and closed conformational states, making it possible to get stuck in
328 one particular conformation.



329
330 **Figure 5** Figures (a) and (b) display the structure of the Nav1.2 protein in its wild-type form, highlighting
331 the interaction between *S1336Y* and D1474. (c) Distance between *S1336Y* and D1474 for both the WT (in
332 black) and *S1336Y* variant (in green) plotted against the simulation time. The plot indicates that the distance
333 between these residues is shorter in the variant compared to the WT. (d) Box plot of the solvent accessible

334 surface area (SASA) for the inactivation gate in both the WT (in black) and *S1336Y* variant (in green) form.
335 The plot shows that the SASA of the inactivation gate is lower in the variant compared to the WT.


336
337 **Changes in compactness in opposite directions for GoF V208E and LoF *R853Q* at the voltage**
338 **sensing domain**

339 To understand the molecular mechanism associated with, GoF variant *V208E* and LoF *R853Q*,
340 both located in voltage-sensing domains (VSD) (VSD-1 and VSD-2, respectively) we focused on
341 structural changes and stability of these domains.

342 We-examined the local structural flexibility and stability of these variant structures by considering
343 the number of hydrogen bonds formed by *V208E* and *R853Q* within a 3.5 Å distance within
344 voltage-sensing domains, as shown in Figures 8b and 8d. A distance cutoff of 3.5 Å and an angle
345 cut-off of 30° was employed to calculate these interactions. Our results indicated that *V208E* has
346 fewer and weaker interactions compared to the wild-type, while *R853Q* formed two new hydrogen
347 bond interactions (Q853-L849 and Q853-S834). Next, we calculated the radius of gyration of the
348 voltage sensing domain taking the main chain of the protein to evaluate how these interactions
349 affect the dynamics, compactness, and stability of the voltage sensing domains. As shown in Figure
350 6c, VSD-2 of *R853Q* was more compact than the wild-type, suggesting increased stability.
351 Conversely, VSD-1 of *V208E* was less compact (Figure 6a), indicating instability and suggesting
352 a flexible voltage-sensing domain. We further performed Wilcoxon rank sum test for radius of
353 gyration for both comparisons: WT and *V208E*; WT and *R853Q* and observed P-value of 3.59 x
354 10¹⁷⁶ and 6.03 x 10²¹² respectively suggesting that these results are significant.

355 Experimental evidence demonstrates that *V208E* shifts the activation curve(38), with the
356 hyperpolarizing effect which may facilitate easier and sooner activation of the channel thus
357 resulting in GoF, however for *R853Q* it was observed to have a hyperpolarizing shift of

358 inactivation(39) suggesting reduced number of channel openings, and thus, resulting in LoF. Our
359 MD results also reveal opposite molecular mechanisms for *R853Q* and *V208E*, where *V208E* was
360 observed to have a slightly unstable VSD-1. However, *R853Q* has more stability in VSD-2
361 compared to WT. This instability of VSD-1 for the *V208E* variant might help the channel to
362 activate sooner resulting in GoF, while increased stability of VSD-2 for *R853Q* might help to
363 stabilize the inactivated state. Our results suggest that the hyperpolarizing shift of activation
364 observed in *V208E* may be due to the decreased stability of the VSD-1, while the hyperpolarizing
365 shift of inactivation observed in *R853Q* may be due to the increased stability of VSD-2.



366
367 **Figure 6** a) Box plot showing the radius of gyration (R_g) of voltage sensing domain 1 for WT (black) and *V208E*
368 (blue). b) Hydrogen bond occupancy (%) formed between V208 and amino-acids within 3.5 Å distance cutoff of
369 *V208E*: black (WT), blue (*V208E*) c) Radius of gyration of voltage sensing domain 2 for WT (black) and *R853Q*
370 structure (magenta) d) Hydrogen bond occupancy (%) formed between R853 and amino-acids within 3.5 Å
371 distance cutoff of *R853Q*: black (WT), magenta (*R853Q*).
372

373 **DISCUSSIONS**

374

375 Despite advancements in predicting variant pathogenicity for the *SCN2A* gene using computational
376 methods, understanding the exact biophysical disease mechanism at an atomic level remains
377 challenging. Current classifications often denote variants as either gain or loss, which overlooks
378 the crucial structural information associated with these variants. To ensure effective treatment and
379 offer informed genetic counseling, it is imperative to understand the molecular-level alterations in
380 the channel function caused by specific genetic variations. Previous computational studies on
381 *SCN2A* focused on understanding ion channel dynamics and very few studies performed MD
382 simulations to understand structural changes due to *SCN2A* mutations. One such recent study
383 performed MD simulations to predict the functional outcome of variants but was limited short
384 simulation scale and absence of membrane. limited to a short time scale. In this study, we reveal
385 molecular mechanisms associated with four *SCN2A* variants using *in-silico* modeling. In summary,
386 observed changes in specific regions for each variant could affect their function. For instance, in
387 the *R937C* variant, we identified a loss of two charged interactions, leading to a shift in the
388 selectivity filter's environment from neutral to negative, potentially hindering ion flow. In the
389 *S1336Y* variant, we observed an additional interaction at the inactivation gate, possibly affecting
390 its ability to switch between different conformations. The *V208E* and *R853Q* variants, located in
391 voltage-sensing domains (VSD), had opposite functional effects: *V208E* displayed a gain-of-
392 function (GoF), while *R853Q* showed a loss-of-function (LoF). Our analysis revealed structural
393 changes in VSD for both variants, suggesting their impact on protein function. We also observed
394 that two LoF variants (*R853Q* and *R937C*) had different molecular mechanisms, which provides a
395 piece of evidence that two variants with the same functional effect may have different biophysical
396 properties and possibly different disease mechanisms.

397 It is important to note that this study has limitations. Due to computational resource constraints,
398 our simulations were limited to 500 ns, and although stable, longer simulations could capture
399 additional phenomena like ion transport and gate opening/closing. Despite the considerable size
400 of the sodium ion channel protein, we conducted three replicas for each system, each lasting 500
401 ns for each variant focusing on the transmembrane region of the protein, which was not done in
402 prior MD studies.

403 Despite some limitations, our findings provide insights into the potential mechanisms for four
404 variants, providing explanations for the observed electrophysiological outcomes. This study
405 contributes to a better understanding of how *SCN2A* variants lead to different diseases,
406 emphasizing the elucidation of biophysical properties that underlie possible disease mechanisms,
407 and potentially aid in improving diagnosis and treatment approaches for patients with *SCN2A*-
408 related disorders.

409 METHODS

410 Variant selection

411 Based on these three criteria, we identified four missense variants: *V208E*, *R853Q*, *R937C*, and
412 *S1336Y* each associated with a different functional outcome, which we incorporated into our study
413 and are described in Table 1. Our selection was based on three criteria. First, the variant must have
414 been experimentally functionally tested, with literature having reached agreement on its either GoF
415 or LoF effect. Second, the variant must have been detected in multiple patients and these patients
416 should exhibit diverse clinical phenotypes. This second requirement stems from the observations
417 of correlations between specific clinical phenotypes and protein functions (LoF/GoF/Mixed)(19),
418 therefore the associated phenotypes could provide supporting evidence for the different molecular
419 changes of the selected variants. The selected variants should represent different phenotypes as

420 represented in Table 1. Third and last criterion, in alignment with the suggestions from past
421 research that the functional impacts of these variants may correlate with their three-dimensional
422 localization within the Nav1.2 protein structure, we ensured that the selected variants were located
423 at different protein domains.

424
425 **Table 1** List of selected variants, their clinical annotations, and their outcomes in experimental
426 functional tests.


Variant	Patients	Phenotype	In vitro electrophysiological read-outs	Effect	Location
<i>R937C</i>	2	ASD	Whole cell current = 0; loss of conductance(36).	LoF	Selectivity Filter (SF)
<i>V208E</i>	2	BFNIE	Hyperpolarizing shift of activation(38).	GoF	Voltage Sensing Domain 1 (VSD-1)
<i>S1336Y</i>	3	EOEE	Smaller current density; hyperpolarized voltage dependence of activation, depolarized shift in the voltage dependence of inactivation.(37)	GoF/Mixed	Inactivation Gate (IG)
<i>R853Q</i>	15	DEE	Narrower voltage range for channel activation, slower recovery from fast inactivation, enhanced slow inactivation, hyperpolarizing shift of inactivation. ^{22,37}	LoF	Voltage Sensing Domain 2 (VSD-2)

427 Phenotypes abbreviations are ASD: autism spectrum disorder; BFNIE: benign familial neonatal-infantile epilepsy; EOEE
428 late-onset epileptic encephalopathy and d) autism spectrum disorder; DEE developmental epileptic encephalopathy.

429 **Modeling of the Nav1.2 protein structure**

430 In this work, our goal was to simulate the Nav1.2 protein in the open conformation to study its
431 dynamics in the wild-type (WT) and in the four mutants. As there are no resolved structures of
432 Nav1.2 in the open conformation, we used homology modeling to model the Nav1.2 structure.(31),
433 onto a recently crystallized open conformation structure of SCN5A gene protein, Nav1.5(40).
434 Homology modeling is a valid approach given the significant sequence similarity observed among
435 human Nav channels in the transmembrane region, which ranges from 85% to 91%. This high level
436 of similarity ensures a consistent and reliable output from the comparative modeling process(41).
437 We performed homology modeling using *Swiss model* application and structurally aligned the
438 modeled Nav1.2 and the crystal structure of Nav1.2 (PDB-ID: 6j8e) . The aligned structures have

439 a RMSD value of 0.98 Å, indicative of a good alignment. We did notice a slight difference in
440 conformation between the structures at the inactivation gate as shown by the dotted circle in Figure
441 7b. Moving forward, we used the modeled Nav1.2 structure as the initial structure for all our MD
442 simulations.



443
444 **Figure 7** Structural alignment of the homology modeled structure of Nav1.2 protein (green) on the Nav1.2
445 protein structure (PDB-ID: 6j8e, magenta). **(a)** Side view; **(b)** Top view where dotted region represents the
446 difference in inactivation gate region conformation


447 **Protein-membrane setup**

448 The setup for our MD simulations was done according to the standard protocol for protein-
449 membrane systems, as follows. We constructed five Nav1.2 protein membrane models (WT and
450 four mutants) using the Charmm-GUI web server's membrane builder(42) application. Only the
451 transmembrane region, including the pore and voltage sensing domains, was considered for system
452 construction. The PPM(positioning of proteins in membranes) server within Charmm-GUI was
453 used to predict the protein's membrane-interacting region. The resulting protein-membrane
454 systems consisted of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) lipid molecules,
455 with dimensions of 185 x185 x186 Å³, and were solvated with TIP3 water molecules. 0.15 M NaCl

456 ions were added to neutralize the system. After system assembly, we performed all-atom molecular
457 dynamics simulations using Gromacs 2021 software(43) and charmm36 forcefield(44). The
458 steepest descent algorithm was used for energy minimization of each system for 5000 steps. To
459 equilibrate the systems, we followed six consecutive equilibration steps, gradually decreasing the
460 harmonic restraint for proteins and lipids. The equilibration steps are summarized in
461 (Supplementary Table 1), with the first two steps carried out in the NVT (constant volume,
462 temperature, and particle number) ensemble and the remaining four steps in the NPT (constant
463 pressure, temperature, and particle number) isobaric-isothermal ensemble.(45)

464
465 **Gromacs simulation protocol**

466 After performing the energy minimization and the equilibration steps, we carried out isobaric-
467 isothermal (NPT) production runs for each system using 2 fs steps, employing semi-isotropic
468 Parrinello-Rahman(46) pressure coupling at a pressure of 1 bar. To constrain the bonds involving
469 hydrogen atoms, we used the LINCS(47) algorithm. Nose-Hoover(45) temperature coupling was
470 used to maintain the temperature of the models. The van der Waals and electrostatic interactions
471 were truncated at a cutoff of 12 Å, and the Particle Mesh Ewald (PME)(48) method was used to
472 handle long-range electrostatic interactions with periodic boundary conditions. A representative
473 initial configuration for the WT system is presented in Figure 8. To ensure the reproducibility and
474 reliability of our results, we performed two additional replicas of each system for 500 ns.



475

476 **Figure 8** a) Top view of the Nav1.2 model. Initial WT protein conformation with the four voltage-sensing
477 domains (VSD) and the inactivation gate (IG) colored in orange and green, respectively. The four residues whose
478 variants are considered in this study are highlighted through sphere representation. b) Side view of the WT
479 protein-membrane set up at 0ns.

480

481 **Analysis of MD trajectories**

482 All the analyses were carried out using embedded Gromacs modules in the Gromacs simulation
483 package and Visual Molecular Dynamics (VMD). We analyzed our files using *gmx_rms*,
484 *gmx_rmsf*, *gmx_sham*, *gmx_gyrate*, *gmx_anaeig*, *gmx_covar*, *gmx_sasa* to extract root mean
485 square deviation, root mean square fluctuations, radius of gyration, solvent accessible surface area,
486 etc. All the graphs were plotted using R (version 4.2.0). Visualizations were done using VMD
487 software (version 1.9.4)(49). The pore radius was calculated using the *hole* program with default
488 settings(50).

489 **2.6. Principal components analysis (PCA) and Free energy landscape (FEL)**

490 We calculated principal component analysis (PCA) of C_α atoms for WT and mutants. We used
491 the *gmx_covar* module which performs calculation and diagonalization of the covariance matrix
492 and outputs the corresponding eigenvectors and eigenvalues based upon positional fluctuations of
493 C_α atoms as described as $C_{ij} = \langle (x_i - \langle x_i \rangle) (x_j - \langle x_j \rangle) \rangle$ where x_i/x_j is the coordinate of i/j_{th} atom and
494 < > represents ensemble average.

495 We calculated the Free Energy Landscape (FEL), which is useful for understanding the stability,
496 folding, and extracting minimal energy conformation of a protein. The FEL can be constructed
497 using the following equation: $G(x) = -k_B T \ln P(x)$ here, k_B represents the Boltzmann constant,
498 T represents the absolute temperature, and $P(x)$ represents the probability distribution of the
499 molecular system along the principal components (PCs).

500

501 **Acknowledgment**

502 I.N.S. is funded, in part, by the Ambrose Monell Cancer Genomic Medicine Fellowship and the
503 NIH National Institute of General Medical Sciences (NIGMS) Maximizing Opportunities for
504 Scientific and Academic Independent Careers (MOSAIC) K99/R00 grant – 1K99GM143552.

505

506 **References**

- 507 (1) Catterall, W. A. Cellular and Molecular Biology of Voltage-Gated Sodium Channels.
508 *Physiological reviews* **1992**, 72 (suppl_4), S15–S48.
- 509 (2) Marban, E.; Yamagishi, T.; Tomaselli, G. F. Structure and Function of Voltage-gated
510 Sodium Channels. *The Journal of physiology* **1998**, 508 (3), 647–657.
- 511 (3) Payandeh, J.; Scheuer, T.; Zheng, N.; Catterall, W. A. The Crystal Structure of a Voltage-
512 Gated Sodium Channel. *Nature* **2011**, 475 (7356), 353–358.
- 513 (4) Chahine, M.; Chatelier, A.; Babich, O.; Krupp, J. J. Voltage-Gated Sodium Channels in
514 Neurological Disorders. *CNS & Neurological Disorders-Drug Targets (Formerly Current*
515 *Drug Targets-CNS & Neurological Disorders)* **2008**, 7 (2), 144–158.
- 516 (5) Sanders, S. J.; Campbell, A. J.; Cottrell, J. R.; Moller, R. S.; Wagner, F. F.; Auldrige, A. L.;
517 Bernier, R. A.; Catterall, W. A.; Chung, W. K.; Empfield, J. R. Progress in Understanding
518 and Treating SCN2A-Mediated Disorders. *Trends in neurosciences* **2018**, 41 (7), 442–456.
- 519 (6) Reynolds, C.; King, M. D.; Gorman, K. M. The Phenotypic Spectrum of SCN2A-Related
520 Epilepsy. *European Journal of Paediatric Neurology* **2020**, 24, 117–122.
- 521 (7) Herlenius, E.; Heron, S. E.; Grinton, B. E.; Keay, D.; Scheffer, I. E.; Mulley, J. C.; Berkovic,
522 S. F. SCN2A Mutations and Benign Familial Neonatal-infantile Seizures: The Phenotypic
523 Spectrum. *Epilepsia* **2007**, 48 (6), 1138–1142.
- 524 (8) Liao, Y.; Anttonen, A.-K.; Liukkonen, E.; Gaily, E.; Maljevic, S.; Schubert, S.; Bellan-Koch,
525 A.; Petrou, S.; Ahonen, V.; Lerche, H. SCN2A Mutation Associated with Neonatal
526 Epilepsy, Late-Onset Episodic Ataxia, Myoclonus, and Pain. *Neurology* **2010**, 75 (16),
527 1454–1458.

528 (9) Shi, X.; Yasumoto, S.; Kurahashi, H.; Nakagawa, E.; Fukasawa, T.; Uchiya, S.; Hirose, S.
529 Clinical Spectrum of *SCN2A* Mutations. *Brain and Development* **2012**, *34* (7), 541–545.

530 (10) Reynolds, C.; King, M. D.; Gorman, K. M. The Phenotypic Spectrum of *SCN2A*-Related
531 Epilepsy. *European Journal of Paediatric Neurology* **2020**, *24*, 117–122.

532 (11) Misra, S. N.; Kahlig, K. M.; George Jr, A. L. Impaired NaV1.2 Function and Reduced Cell
533 Surface Expression in Benign Familial Neonatal-infantile Seizures. *Epilepsia* **2008**, *49* (9),
534 1535–1545.

535 (12) Lauxmann, S.; Verbeek, N. E.; Liu, Y.; Zaichuk, M.; Müller, S.; Lemke, J. R.; van
536 Kempen, M. J.; Lerche, H.; Hedrich, U. B. Relationship of Electrophysiological
537 Dysfunction and Clinical Severity in *SCN2A*-related Epilepsies. *Human mutation* **2018**, *39*
538 (12), 1942–1956.

539 (13) Mason, E. R.; Wu, F.; Patel, R. R.; Xiao, Y.; Cannon, S. C.; Cummins, T. R. Resurgent and
540 Gating Pore Currents Induced by *de Novo* *SCN2A* Epilepsy Mutations. *ENeuro* **2019**, *6* (5).

541 (14) Brunklaus, A.; Du, J.; Steckler, F.; Ghanty, I. I.; Johannessen, K. M.; Fenger, C. D.;
542 Schorge, S.; Baez-Nieto, D.; Wang, H.; Allen, A. Biological Concepts in Human Sodium
543 Channel Epilepsies and Their Relevance in Clinical Practice. *Epilepsia* **2020**, *61* (3), 387–
544 399.

545 (15) Wolff, M.; Johannessen, K. M.; Hedrich, U. B.; Masnada, S.; Rubboli, G.; Gardella, E.;
546 Lesca, G.; Ville, D.; Milh, M.; Villard, L. Genetic and Phenotypic Heterogeneity Suggest
547 Therapeutic Implications in *SCN2A*-Related Disorders. *Brain* **2017**, *140* (5), 1316–1336.

548 (16) Eijkelkamp, N.; Linley, J. E.; Baker, M. D.; Minett, M. S.; Cregg, R.; Werdehausen, R.;
549 Rugiero, F.; Wood, J. N. Neurological Perspectives on Voltage-Gated Sodium Channels.
550 *Brain* **2012**, *135* (9), 2585–2612.

551 (17) Hollingsworth, S. A.; Dror, R. O. Molecular Dynamics Simulation for All. *Neuron* **2018**, *99*
552 (6), 1129–1143.

553 (18) Karplus, M.; Petsko, G. A. Molecular Dynamics Simulations in Biology. *Nature* **1990**, *347*
554 (6294), 631–639.

555 (19) McCusker, E. C.; Bagnérés, C.; Naylor, C. E.; Cole, A. R.; D'avanzo, N.; Nichols, C. G.;
556 Wallace, B. A. Structure of a Bacterial Voltage-Gated Sodium Channel Pore Reveals
557 Mechanisms of Opening and Closing. *Nature communications* **2012**, *3* (1), 1102.

558 (20) Ulmschneider, M. B.; Bagnérés, C.; McCusker, E. C.; DeCaen, P. G.; Delling, M.;
559 Clapham, D. E.; Ulmschneider, J. P.; Wallace, B. A. Molecular Dynamics of Ion Transport
560 through the Open Conformation of a Bacterial Voltage-Gated Sodium Channel.
561 *Proceedings of the National Academy of Sciences* **2013**, *110* (16), 6364–6369.

562 (21) Qiu, H.; Shen, R.; Guo, W. Ion Solvation and Structural Stability in a Sodium Channel
563 Investigated by Molecular Dynamics Calculations. *Biochimica et Biophysica Acta (BBA)-*
564 *Biomembranes* **2012**, *1818* (11), 2529–2535.

565 (22) Chakrabarti, N.; Ing, C.; Payandeh, J.; Zheng, N.; Catterall, W. A.; Pomès, R. Catalysis of
566 Na⁺ Permeation in the Bacterial Sodium Channel NaVAb. *Proceedings of the National*
567 *Academy of Sciences* **2013**, *110* (28), 11331–11336.

568 (23) Ahmed, M.; Jalily Hasani, H.; Ganesan, A.; Houghton, M.; Barakat, K. Modeling the
569 Human Nav1.5 Sodium Channel: Structural and Mechanistic Insights of Ion Permeation
570 and Drug Blockade. *Drug Design, Development and Therapy* **2017**, 2301–2324.

571 (24) Zhang, J.; Mao, W.; Ren, Y.; Sun, R.-N.; Yan, N.; Gong, H. Simulating the Ion Permeation
572 and Ion Selection for a Eukaryotic Voltage-Gated Sodium Channel NaVPaS. *Protein & cell*
573 **2018**, *9* (6), 580–585.

574 (25) Pan, X.; Li, Z.; Huang, X.; Huang, G.; Gao, S.; Shen, H.; Liu, L.; Lei, J.; Yan, N. Molecular
575 Basis for Pore Blockade of Human Na⁺ Channel Nav1.2 by the μ -Conotoxin KIIIA.
576 *Science* **2019**, *363* (6433), 1309–1313.

577 (26) Nguyen, P. T.; DeMarco, K. R.; Vorobyov, I.; Clancy, C. E.; Yarov-Yarovoy, V. Structural
578 Basis for Antiarrhythmic Drug Interactions with the Human Cardiac Sodium Channel.
579 *Proceedings of the National Academy of Sciences* **2019**, *116* (8), 2945–2954.

580 (27) Gao, S.; Na, R.; Yang, L.; Yu, H.; Zhao, X.; Huang, X. Investigation of Binding Modes of
581 Spider Toxin–Human Voltage-Gated Sodium Channel Subtype 1.7. *Journal of*
582 *Biomolecular Structure and Dynamics* **2021**, *39* (14), 4981–4989.

583 (28) Catterall, W. A. Voltage-gated Sodium Channels at 60: Structure, Function and
584 Pathophysiology. *The Journal of physiology* **2012**, *590* (11), 2577–2589.

585 (29) Catterall, W. A. From Ionic Currents to Molecular Mechanisms: The Structure and
586 Function of Voltage-Gated Sodium Channels. *Neuron* **2000**, *26* (1), 13–25.

587 (30) Begemann, A.; Acuña, M. A.; Zweier, M.; Vincent, M.; Steindl, K.; Bachmann-Gagescu,
588 R.; Hackenberg, A.; Abela, L.; Plecko, B.; Kroell-Seger, J. Further Corroboration of
589 Distinct Functional Features in SCN2A Variants Causing Intellectual Disability or Epileptic
590 Phenotypes. *Molecular Medicine* **2019**, *25* (1), 1–15.

591 (31) Thompson, C. H.; Ben-Shalom, R.; Bender, K. J.; George, A. L. Alternative Splicing
592 Potentiates Dysfunction of Early-Onset Epileptic Encephalopathy SCN2A Variants. *Journal*
593 *of General Physiology* **2020**, *152* (3).

594 (32) Lauxmann, S.; Verbeek, N. E.; Liu, Y.; Zaichuk, M.; Müller, S.; Lemke, J. R.; van
595 Kempen, M. J.; Lerche, H.; Hedrich, U. B. Relationship of Electrophysiological
596 Dysfunction and Clinical Severity in SCN2A-related Epilepsies. *Human mutation* **2018**, *39*
597 (12), 1942–1956.

598 (33) Jiang, D.; Banh, R.; El-Din, T. M. G.; Tonggu, L.; Lenaeus, M. J.; Pomès, R.; Zheng, N.;
599 Catterall, W. A. Open-State Structure and Pore Gating Mechanism of the Cardiac Sodium
600 Channel. *Cell* **2021**, *184* (20), 5151–5162.

601 (34) Wu, E. L.; Cheng, X.; Jo, S.; Rui, H.; Song, K. C.; Dávila-Contreras, E. M.; Qi, Y.; Lee, J.;
602 Monje-Galvan, V.; Venable, R. M. CHARMM-GUI Membrane Builder toward Realistic
603 Biological Membrane Simulations. **2014**.

604 (35) Lindahl, E.; Hess, B.; Van Der Spoel, D. GROMACS 3.0: A Package for Molecular
605 Simulation and Trajectory Analysis. *Molecular modeling annual* **2001**, *7* (8), 306–317.

606 (36) Huang, J.; MacKerell Jr, A. D. CHARMM36 All-atom Additive Protein Force Field:
607 Validation Based on Comparison to NMR Data. *Journal of computational chemistry* **2013**,
608 *34* (25), 2135–2145.

609 (37) Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J.
610 GROMACS: Fast, Flexible, and Free. *Journal of computational chemistry* **2005**, *26* (16),
611 1701–1718.

612 (38) Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics. *Journal of*
613 *molecular graphics* **1996**, *14* (1), 33–38.

614 (39) Smart, O. S.; Neduvvelil, J. G.; Wang, X.; Wallace, B.; Sansom, M. S. HOLE: A Program
615 for the Analysis of the Pore Dimensions of Ion Channel Structural Models. *Journal of*
616 *molecular graphics* **1996**, *14* (6), 354–360.

617 (40) Ganguly, S.; Thompson, C. H.; George Jr, A. L. Enhanced Slow Inactivation Contributes to
618 Dysfunction of a Recurrent SCN2A Mutation Associated with Developmental and Epileptic
619 Encephalopathy. *The Journal of Physiology* **2021**, *599* (18), 4375–4388.